OX2R-004: Phase 1 Wet-Lab — Reference + Stabilised Variant (S1)

Ox2r-004: Phase 1 Wet-lab — Reference + Stabilised Variant (S1)

OX2R

Peptide therapeutics — CNS / ADHD / orexin receptor agonism

OX2R-004-S1 is a stabilised ncAA variant (Ac + D-Arg4 + D-Tyr5) of OX2R-004, designed for ADHD via the orexin pathway and engineered to address the Gate 6 proteolytic-stability flag (predicted serum t1/2 15 to 55 min, cleavage sites 34 to 28). Phase 1 wet-lab tests OX2R-004-S1 against the natural-AA parent OX2R-004 and Orexin-B (native ligand) at Adaptyv (BLI + OX1R counter-screen), with cAMP HTRF at Ginkgo on top binders and plasma-stability LC-MS. Comparative output addresses both the stability and OX1R-selectivity flags from the computational pipeline.

Description

Team

0xda935…da668

Owner

Experiment Cost

$7,750.00

Project Score

Updated Sep 11, 2026

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Project Progress

All updates

All categories

Timeline

Ox2r-004: Phase 1 Wet-lab — Reference + Stabilised Variant (S1)

OX2R

Peptide therapeutics — CNS / ADHD / orexin receptor agonism

Description

Team

0xda935…da668

Owner

Experiment Cost

$7,750.00

Project Score

Updated Sep 11, 2026

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Project Progress

All updates

All categories

Timeline

Rationale

The project is entirely at the computational/in silico design stage with no wet-lab experiments conducted. All data are computational predictions (PRODIGY binding energy, MD simulations, ADMET predictions, immunogenicity screening, solubility/aggregation scoring). The project explicitly states "No wet-lab experiments, binding assays, cell-based assays, animal studies, or any empirical testing has been performed," placing it squarely at TRL 1 under the decision tree's first question.

Assessment

Low Confidence

RecommendationPROMOTE

Total Score3.85

Overall Assessment

OX2R-004 achieves a final weighted score of 3.85 out of 5.00, reflecting a promising but early-stage TRL 1 project with meaningful strengths and identifiable risks. The project's strongest dimension is therapeutic relevance (score 4/5, weighted 2.40): the orexin system dysfunction hypothesis for ADHD is scientifically grounded, the target is validated by multiple clinical-stage competitors, and the peptide agonist approach is differentiated. The intellectual property position is also strong (score 4/5, weighted 1.00), as no peptide OX2R agonists exist in clinical development and the de novo sequence plus stabilization modifications offer clear composition-of-matter novelty. Therapeutic optionality is moderate (score 3/5, weighted 0.45), limited by the peptide modality's inherent CNS delivery challenges and the narrow applicability of the specific scaffold beyond orexin-related indications. Key risks that prevent higher scores include: (1) the G6 proteolytic stability failure (~5 min serum half-life) representing a fundamental development blocker; (2) the G8b OX1R cross-reactivity concern (90-100% pocket conservation) that may preclude selective OX2R engagement; (3) the complete absence of wet-lab validation — all data is computational; and (4) the BBB penetration gap requiring unproven intranasal delivery. The project has a well-structured computational pipeline and clear experimental validation plan (G9), but advancement depends critically on wet-lab confirmation of binding/function and successful stabilization engineering. At TRL 1, the concept is scientifically sound and novel, but the path to therapeutic viability carries substantial technical risk.

Weighted Score

Therapeutic Relevance

The mechanism is scientifically plausible and targets a biologically relevant pathway: orexin system dysfunction in ADHD is supported by evidence that drug-naive ADHD children show decreased orexin-A/B levels. OX2R agonism is a validated biological mechanism (endogenous Orexin-B is a natural OX2R agonist with well-characterized signaling). The competitive landscape confirms target relevance — three small-molecule OX2R agonists (TAK-861, ORX750, BP1.15205) are in clinical development, validating OX2R as a druggable target. However, a score of 5 is withheld for several reasons: (1) all clinical-stage OX2R agonists target narcolepsy, not ADHD — the ADHD indication is a novel therapeutic hypothesis without clinical precedent for orexin modulation; (2) the peptide modality faces fundamental challenges (proteolytic instability with ~5 min serum half-life, BBB impermeability requiring unproven intranasal delivery); (3) OX1R cross-reactivity (90-100% binding pocket conservation) raises safety concerns since OX1R activation could produce unwanted effects; and (4) all evidence remains purely computational with no wet-lab validation of binding or functional agonism.

Therapeutic Optionality

Moderate therapeutic optionality. The OX2R agonist mechanism has clear applicability beyond ADHD — narcolepsy type 1 and type 2 are the primary indications being pursued by competitors (TAK-861, ORX750), and orexin system modulation is relevant to excessive daytime sleepiness, hypersomnia, and potentially obesity/metabolic disorders. The peptide platform concept (if stabilization challenges are solved) could theoretically be adapted to other GPCR peptide agonist programs. However, optionality is constrained by: (1) the peptide modality's inherent limitations (proteolytic instability, poor oral bioavailability, BBB impermeability) that would apply across all CNS indications; (2) the OX1R cross-reactivity concern limits the ability to selectively target OX2R vs. dual receptor engagement, narrowing the therapeutic window; (3) the competitive landscape is dominated by small molecules that have inherent advantages in CNS delivery and oral dosing; and (4) the concept flexibility is moderate — the 18-residue peptide scaffold is specific to orexin receptor engagement and does not readily generalize to other target classes without de novo redesign.

Intellectual Property

Strong novelty position. OX2R-004 represents a genuinely novel approach: no peptide OX2R agonists are in clinical development — all competitors are small molecules. The specific 18-residue sequence (KGDRYGVAYEHGGAQPFK) is a de novo designed peptide distinct from natural Orexin-B (28 residues), providing composition-of-matter patentability. The stabilized variant OX2R-004-S1 with specific D-amino acid substitutions (D-Arg4, D-Tyr5) and N-acetylation adds further IP layers. The intranasal delivery strategy with chitosan nanoparticles for CNS targeting could support formulation patents. However, a score of 5 is withheld because: (1) the concept of peptide agonists for orexin receptors is not fundamentally novel — it builds on well-known endogenous ligand biology; (2) prior art exists around orexin-derived peptide fragments and modifications in academic literature; (3) the 90-100% OX2R/OX1R binding pocket conservation means any peptide targeting the orthosteric site faces similar design constraints, potentially limiting freedom-to-operate if competitors pursue similar peptide approaches; and (4) without wet-lab validation of binding or function, the IP position rests on computational predictions that may not translate to patentable claims of therapeutic utility.